Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs Kyndryl Holdings Inc (KD) Price & Performance

Quest Diagnostics IncTrade
Kyndryl Holdings IncTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs Kyndryl Holdings Inc — how do they compare? Quest Diagnostics Inc trades at $237.08 (market cap $26.21B), while Kyndryl Holdings Inc trades at $12.74 (market cap $2.91B). The key difference: Quest Diagnostics Inc is far larger — about 9× Kyndryl Holdings Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.

DGXKD
Market Cap
$26.21B$2.91B
Sector
HealthTechnology
52-Week High
$238.50$33.14
52-Week Low
$173.49$10.59
Enterprise Value
$31.97B$5.74B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.

DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.

Kyndryl Holdings Inc

Kyndryl (KD) trades at $13.63, down 2.78% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company shows improving profitability with 2025 net income of $252M after years of losses, though recent Q1 2027 earnings missed expectations. The acquisition of Healthcare IT Leaders and new AI services demonstrate strategic growth initiatives.

While analyst consensus leans Hold (71%) with a $13.50 price target near current levels, improving cash flow and debt management provide stability. Key risks include revenue declines, ongoing investigations, and competitive pressures in IT services. The stock presents a turnaround story with moderate upside potential balanced by execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About Kyndryl Holdings Inc

Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.

Read more on KD